Antagonism of BST-2/tetherin is a conserved function of the Env glycoprotein of primary HIV-2 isolates

Journal of Virology

Volumn 90, Issue 24, 2016, Pages 11062-11074

  Chen, Chia Yen ^a   Shingai, Masashi ^a   Welbourn, Sarah ^a   Martin, Malcolm A ^a   Borrego, Pedro ^b   Taveira, Nuno ^b,c   Strebel, Klaus ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

^c INSTITUTO SUPERIOR DE CIÊNCIAS DA SAÚDE EGAS MONIZ   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

BST 2 PROTEIN; ROD10 PROTEIN; ROD14 PROTEIN; TETHERIN; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; BST2 PROTEIN, HUMAN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; LEUKOCYTE ANTIGEN; VIRUS ENVELOPE PROTEIN;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 2; MOLECULAR CLONING; MOLECULAR EVOLUTION; NONHUMAN; PHYLOGENY; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN SUBUNIT; SEQUENCE HOMOLOGY; VIRUS ENVELOPE; VIRUS ISOLATION; VIRUS RELEASE; CLASSIFICATION; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; HELA CELL LINE; HOST PATHOGEN INTERACTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; ISOLATION AND PURIFICATION; MUTATION; SEQUENCE ALIGNMENT; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS; VIROLOGY; VIRUS REPLICATION;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIGENS, CD; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENE EXPRESSION REGULATION; GPI-LINKED PROTEINS; HEK293 CELLS; HELA CELLS; HIV INFECTIONS; HIV-2; HOST-PATHOGEN INTERACTIONS; HUMANS; MUTAGENESIS, SITE-DIRECTED; MUTATION; PHYLOGENY; SEQUENCE ALIGNMENT; SIGNAL TRANSDUCTION; VIRUS RELEASE; VIRUS REPLICATION;

EID: 85001093586     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01451-16     Document Type: Article

References (55)

1. Sharp PM, Hahn BH. 2011. Origins of HIV and the AIDS pandemic. Cold Spring Harb Perspect Med 1:a006841.
2. de Silva TI, Cotten M, Rowland-Jones SL. 2008. HIV-2: the forgotten AIDS virus. Trends Microbiol 16:588-595. http://dx.doi.org/10.1016/j.tim.2008.09.003.
3. Ayouba A, Akoua-Koffi C, Calvignac-Spencer S, Esteban A, Locatelli S, Li H, Li Y, Hahn BH, Delaporte E, Leendertz FH, Peeters M. 2013. Evidence for continuing cross-species transmission of SIVsmm to humans: characterization of a new HIV-2 lineage in rural Cote d'Ivoire. AIDS 27:2488-2491. http://dx.doi.org/10.1097/01.aids.0000432443.22684.50.
4. Strebel K. 2013. HIV accessory proteins versus host restriction factors. Curr Opin Virol 3:692-699. http://dx.doi.org/10.1016/j.coviro.2013.08.004.
5. Garcia JV, Miller AD. 1991. Serine phosphorylation-independent downregulation of cell-surface CD4 by nef. Nature 350:508-511. http://dx.doi.org/10.1038/350508a0.
6. Willey RL, Maldarelli F, Martin MA, Strebel K. 1992. Human immunodeficiency virus type 1 Vpu protein induces rapid degradation of CD4. J Virol 66:7193-7200.
7. Dimitrov DS, Willey RL, Martin MA, Blumenthal R. 1992. Kinetics of HIV-1 interactions with sCD4 and CD4+ cells: implications for inhibition of virus infection and initial steps of virus entry into cells. Virology 187:398-406. http://dx.doi.org/10.1016/0042-6822(92)90441-Q.
8. Bour S, Schubert U, Peden K, Strebel K. 1996. The envelope glycoprotein of human immunodeficiency virus type 2 enhances viral particle release: a Vpu-like factor? J Virol 70:820-829.
9. Bour S, Strebel K. 1996. The human immunodeficiency virus (HIV) type 2 envelope protein is a functional complement to HIV type 1 Vpu that enhances particle release of heterologous retroviruses. J Virol 70:8285-8300.
10. Jia B, Serra-Moreno R, Neidermyer W, Rahmberg A, Mackey J, Fofana IB, Johnson WE, Westmoreland S, Evans DT. 2009. Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/ BST2. PLoS Pathog 5:e1000429. http://dx.doi.org/10.1371/journal.ppat.1000429.
11. Zhang F, Wilson SJ, Landford WC, Virgen B, Gregory D, Johnson MC, Munch J, Kirchhoff F, Bieniasz PD, Hatziioannou T. 2009. Nef proteins from simian immunodeficiency viruses are tetherin antagonists. Cell Host Microbe 6:54-67. http://dx.doi.org/10.1016/j.chom.2009.05.008.
12. Sauter D, Schindler M, Specht A, Landford WN, Munch J, Kim KA, Votteler J, Schubert U, Bibollet-Ruche F, Keele BF, Takehisa J, Ogando Y, Ochsenbauer C, Kappes JC, Ayouba A, Peeters M, Learn GH, Shaw G, Sharp PM, Bieniasz P, Hahn BH, Hatziioannou T, Kirchhoff F. 2009. Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains. Cell Host Microbe 6:409-421 http://dx.doi.org/10.1016/j.chom.2009.10.004.
13. Serra-Moreno R, Zimmermann K, Stern LJ, Evans DT. 2013. Tetherin/ BST-2 antagonism by Nef depends on a direct physical interaction between Nef and tetherin, and on clathrin-mediated endocytosis. PLoS Pathog 9:e1003487. http://dx.doi.org/10.1371/journal.ppat.1003487.
14. Neil SJ, Zang T, Bieniasz PD. 2008. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451:425-430. http://dx.doi.org /10.1038/nature06553.
15. Van Damme N, Goff D, Katsura C, Jorgenson RL, Mitchell R, Johnson MC, Stephens EB, Guatelli J. 2008. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 3:245-252. http://dx.doi.org /10.1016/j.chom.2008.03.001.
16. Ritter GD, Yamshchikov G, Cohen SJ, Mulligan MJ. 1996. Human immunodeficiency virus type 2 glycoprotein enhancement of particle budding: role of the cytoplasmic domain. J Virol 70:2669-2673.
17. Abada P, Noble B, Cannon PM. 2005. Functional domains within the human immunodeficiency virus type 2 envelope protein required to enhance virus production. J Virol 79:3627-3638. http://dx.doi.org/10.1128 /JVI.79.6.3627-3638.2005.
18. Le Tortorec A, Neil SJ. 2009. Antagonism to and intracellular sequestration of human tetherin by the human immunodeficiency virus type 2 envelope glycoprotein. J Virol 83:11966-11978. http://dx.doi.org/10.1128 /JVI.01515-09.
19. Hauser H, Lopez LA, Yang SJ, Oldenburg JE, Exline CM, Guatelli JC, Cannon PM. 2010. HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment. Retrovirology 7:51. http: //dx.doi.org/10.1186/1742-4690-7-51.
20. Gupta RK, Mlcochova P, Pelchen-Matthews A, Petit SJ, Mattiuzzo G, Pillay D, Takeuchi Y, Marsh M, Towers GJ. 2009. Simian immunodeficiency virus envelope glycoprotein counteracts tetherin/BST-2/CD317 by intracellular sequestration. Proc Natl Acad SciUSA106:20889-20894. http://dx.doi.org/10.1073/pnas.0907075106.
21. Serra-Moreno R, Jia B, Breed M, Alvarez X, Evans DT. 2011. Compensatory changes in the cytoplasmic tail of gp41 confer resistance to tetherin/ BST-2 in a pathogenic nef-deleted SIV. Cell Host Microbe 9:46-57. http: //dx.doi.org/10.1016/j.chom.2010.12.005.
22. Lopez LA, Yang SJ, Hauser H, Exline CM, Haworth KG, Oldenburg J, Cannon PM. 2010. Ebola virus glycoprotein counteracts BST-2/Tetherin restriction in a sequence-independent manner that does not require tetherin surface removal. J Virol 84:7243-7255. http://dx.doi.org/10.1128/JVI.02636-09.
23. Noble B, Abada P, Nunez-Iglesias J, Cannon PM. 2006. Recruitment of the adaptor protein 2 complex by the human immunodeficiency virus type 2 envelope protein is necessary for high levels of virus release. J Virol 80:2924-2932. http://dx.doi.org/10.1128/JVI.80.6.2924-2932.2006.
24. Bour S, Akari H, Miyagi E, Strebel K. 2003. Naturally occurring amino acid substitutions in the HIV-2 ROD envelope glycoprotein regulate its ability to augment viral particle release. Virology 309:85-98. http://dx.doi.org/10.1016/S0042-6822(02)00128-9.
25. Marcelino JM, Borrego P, Rocha C, Barroso H, Quintas A, Novo C, Taveira N. 2010. Potent and broadly reactive HIV-2 neutralizing antibodies elicited by a vaccinia virus vector prime-C2V3C3 polypeptide boost immunization strategy. J Virol 84:12429-12436. http://dx.doi.org/10.1128/JVI.01102-10.
26. Borrego P, Calado R, Marcelino JM, Bartolo I, Rocha C, Cavaco-Silva P, Doroana M, Antunes F, Maltez F, Caixas U, Barroso H, Taveira N. 2012 Baseline susceptibility of primary HIV-2 to entry inhibitors. Antivir Ther 17:565-570. http://dx.doi.org/10.3851/IMP1996.
27. Edgar RC. 2004. MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res 32:1792-1797. http://dx.doi.org/10.1093/nar/gkh340.
28. Tamura K, Stecher G, Peterson D, Filipski A, Kumar S. 2013. MEGA6: molecular evolutionary genetics analysis version 6.0. Mol Biol Evol 30: 2725-2729. http://dx.doi.org/10.1093/molbev/mst197.
29. Klimkait T, Strebel K, Hoggan MD, Martin MA, Orenstein JM. 1990. The human immunodeficiency virus type 1-specific protein vpu is required for efficient virus maturation and release. J Virol 64:621-629.
30. Willey RL, Smith DH, Lasky LA, Theodore TS, Earl PL, Moss B, Capon DJ, Martin MA. 1988. In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity. J Virol 62:139-147.
31. Neil SJ, Sandrin V, Sundquist WI, Bieniasz PD. 2007. An interferonalpha-induced tethering mechanism inhibits HIV-1 and Ebola virus particle release but is counteracted by the HIV-1 Vpu protein. Cell Host Microbe 2:193-203. http://dx.doi.org/10.1016/j.chom.2007.08.001.
32. Miyagi E, Andrew AJ, Kao S, Strebel K. 2009. Vpu enhances HIV-1 virus release in the absence of Bst-2 cell surface down-modulation and intracellular depletion. Proc Natl Acad Sci U S A 106:2868-2873. http://dx.doi.org/10.1073/pnas.0813223106.
33. Exline CM, Yang SJ, Haworth KG, Rengarajan S, Lopez LA, Droniou ME, Seclen E, Cannon PM. 2015. Determinants in HIV-2 Env and tetherin required for functional interaction. Retrovirology 12:67. http://dx.doi.org/10.1186/s12977-015-0194-0.
34. Alvarez RA, Hamlin RE, Monroe A, Moldt B, Hotta MT, Rodriguez Caprio G, Fierer DS, Simon V, Chen BK. 2014. HIV-1 Vpu antagonism of tetherin inhibits antibody-dependent cellular cytotoxic responses by natural killer cells. J Virol 88:6031-6046. http://dx.doi.org/10.1128/JVI.00449-14.
35. Arias JF, Heyer LN, von Bredow B, Weisgrau KL, Moldt B, Burton DR, Rakasz EG, Evans DT. 2014. Tetherin antagonism by Vpu protects HIV-infected cells from antibody-dependent cell-mediated cytotoxicity. Proc Natl Acad Sci U S A 111:6425-6430. http://dx.doi.org/10.1073/pnas.1321507111.
36. Pham TN, Lukhele S, Hajjar F, Routy JP, Cohen EA. 2014. HIV Nef and Vpu protect HIV-infected CD4+ T cells from antibody-mediated cell lysis through down-modulation of CD4 and BST2. Retrovirology 11:15. http: //dx.doi.org/10.1186/1742-4690-11-15.
37. Andrew A, Strebel K. 2011. The interferon-inducible host factor bone marrow stromal antigen 2/tetherin restricts virion release, but is it actually a viral restriction factor? J Interferon Cytokine Res 31:137-144. http://dx.doi.org/10.1089/jir.2010.0108.
38. Yang SJ, Lopez LA, Hauser H, Exline CM, Haworth KG, Cannon PM. 2010 Anti-tetherin activities in Vpu-expressing primate lentiviruses. Retrovirology 7:13. http://dx.doi.org/10.1186/1742-4690-7-13.
39. Morrison JH, Guevara RB, Marcano AC, Saenz DT, Fadel HJ, Rogstad DK, Poeschla EM. 2014. Feline immunodeficiency virus envelope glycoproteins antagonize tetherin through a distinctive mechanism that requires virion incorporation. J Virol 88:3255-3272. http://dx.doi.org/10.1128/JVI.03814-13.
40. Yin X, Hu Z, Gu Q, Wu X, Zheng Y-H, Wei P, Wang X. 2014. Equine tetherin blocks retrovirus release and its activity is antagonized by equine infectious anemia virus envelope protein. J Virol 88:1259-1270. http://dx.doi.org/10.1128/JVI.03148-13.
41. Shingai M, Yoshida T, Martin MA, Strebel K. 2011. Some human immunodeficiency virus type 1 Vpu proteins are able to antagonize macaque BST-2 in vitro and in vivo: Vpu-negative simian-human immunodeficiency viruses are attenuated in vivo. J Virol 85:9708-9715. http://dx.doi.org/10.1128/JVI.00626-11.
42. Yoshida T, Kao S, Strebel K. 2011. Identification of residues in the BST-2 TM domain important for antagonism by HIV-1 Vpu using a gain-offunction approach. Front Microbiol 2:1.
43. Kobayashi T, Ode H, Yoshida T, Sato K, Gee P, Yamamoto SP, Ebina H, Strebel K, Sato H, Koyanagi Y. 2011. Identification of amino acids in the human tetherin transmembrane domain responsible for HIV-1 Vpu interaction and susceptibility. J Virol 85:932-945. http://dx.doi.org/10.1128/JVI.01668-10.
44. Gupta RK, Hue S, Schaller T, Verschoor E, Pillay D, Towers GJ. 2009. Mutation of a single residue renders human tetherin resistant to HIV-1 Vpu-mediated depletion. PLoS Pathog 5:e1000443. http://dx.doi.org/10.1371/journal.ppat.1000443.
45. McNatt MW, Zang T, Hatziioannou T, Bartlett M, Fofana IB, Johnson WE, Neil SJ, Bieniasz PD. 2009. Species-specific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variants. PLoS Pathog 5:e1000300. http://dx.doi.org/10.1371/journal.ppat.1000300.
46. Iwabu Y, Fujita H, Kinomoto M, Kaneko K, Ishizaka Y, Tanaka Y, Sata T, Tokunaga K. 2009. HIV-1 accessory protein Vpu internalizes cellsurface BST-2/tetherin through transmembrane interactions leading to lysosomes. J Biol Chem 284:35060-35072. http://dx.doi.org/10.1074/jbc.M109.058305.
47. Skasko M, Wang Y, Tian Y, Tokarev A, Munguia J, Ruiz A, Stephens EB, Opella SJ, Guatelli J. 2012. HIV-1 Vpu protein antagonizes innate restriction factor BST-2 via lipid-embedded helix-helix interactions. J Biol Chem 287:58-67. http://dx.doi.org/10.1074/jbc.M111.296772.
48. Jia X, Weber E, Tokarev A, Lewinski M, Rizk M, Suarez M, Guatelli J, Xiong Y. 2014. Structural basis of HIV-1 Vpu-mediated BST2 antagonism via hijacking of the clathrin adaptor protein complex 1. eLife 3:e02362.
49. Kueck T, Neil SJD. 2012. A cytoplasmic tail determinant in HIV-1 Vpu mediates targeting of tetherin for endosomal degradation and counteracts interferon-induced restriction. PLoS Pathog 8:e1002609. http://dx.doi.org/10.1371/journal.ppat.1002609.
50. Lau D, Kwan W, Guatelli J. 2011. Role of the endocytic pathway in the counteraction of BST-2 by human lentiviral pathogens. J Virol 85:9834-9846 http://dx.doi.org/10.1128/JVI.02633-10.
51. Mitchell RS, Katsura C, Skasko MA, Fitzpatrick K, Lau D, Ruiz A, Stephens EB, Margottin-Goguet F, Benarous R, Guatelli JC. 2009. Vpu antagonizes BST-2-mediated restriction of HIV-1 release via beta-TrCP and endo-lysosomal trafficking. PLoS Pathog 5:e1000450. http://dx.doi.org/10.1371/journal.ppat.1000450.
52. Ruiz A, Hill MS, Schmitt K, Guatelli J, Stephens EB. 2008. Requirements of the membrane proximal tyrosine and dileucine-based sorting signals for efficient transport of the subtype C Vpu protein to the plasma membrane and in virus release. Virology 378:58-68. http://dx.doi.org/10.1016/j.virol.2008.05.022.
53. Sauter D. 2014. Counteraction of the multifunctional restriction factor tetherin. Front Microbiol 5:163.
54. Miyagi E, Andrew A, Kao S, Yoshida T, Strebel K. 2011. Antibodymediated enhancement of HIV-1 and HIV-2 production from BST-2/ tetherin+ cells. J Virol 85:11981-11994. http://dx.doi.org/10.1128/JVI.05176-11.
55. Freed EO, Myers DJ. 1992. Identification and characterization of fusion and processing domains of the human immunodeficiency virus type 2 envelope glycoprotein. J Virol 66:5472-5478.